Hypoxia-Induced Down-Regulation of Neprilysin by Histone Modification in Mouse Primary Cortical and Hippocampal Neurons

Zheng Wang¹, Dehua Yang¹, Xiaojie Zhang², Ting Li², Jia Li², Yu Tang², Weidong Le¹,3

¹ Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³ Department of Neurology, Baylor College of Medicine, Houston, Texas, United States of America

Abstract

Amyloid β-peptide (Aβ) accumulation leads to neurodegeneration and Alzheimer’s disease (AD). Aβ metabolism is a dynamic process in the Aβ production and clearance that requires neprilysin (NEP) and other enzymes to degrade Aβ. It has been reported that NEP expression is significantly decreased in the brain of AD patients. Previously we have documented hypoxia is a risk factor for Aβ generation in vivo and in vitro through increasing Aβ generation by altering β-cleavage and γ-cleavage of APP and down-regulating NEP, and causing tau hyperphosphorylation. Here, we investigated the molecular mechanisms of hypoxia-induced down-regulation of NEP. We found a significant decrease in NEP expression at the mRNA and protein levels after hypoxic treatment in mouse primary cortical and hippocampal neurons. Chromatin immunoprecipitation (ChIP) assays and relative quantitative PCR (q-PCR) revealed an increase of histone H3 lysine9 demethylation (H3K9me2) and a decrease of H3 acetylation (H3-Ace) in the NEP promoter regions following hypoxia. In addition, we found that hypoxia caused up-regulation of histone methyl transferase (HMT) G9a and histone deacetylases (HDACs) HDAC-1. Decreased expression of NEP during hypoxia can be prevented by application with the epigenetic regulators 5-Aza-2′-deoxycytidine (5-Aza), HDACs inhibitor sodium valproate (VA), and siRNA-mediated knockdown of G9a or HDAC1. DNA methylation PCR data do not support that hypoxia affects the methylation of NEP promoters. This study suggests that hypoxia may down-regulate NEP by increasing H3K9me2 and decreasing H3-Ace modulation.

Introduction

A neuropathological hallmark of Alzheimer’s disease (AD) is the presence of amyloid β-peptide (Aβ) plaques, composed mainly of Aβ1-42, and the excessive accumulation of Aβ1-42 is believed to be responsible for the initial event of neurodegeneration in AD [1]. Previously we have documented that hypoxia is a risk factor for Aβ generation in vivo and in vitro through increasing Aβ generation by altering β-cleavage and γ-cleavage of amyloid precursor protein (APP) and down-regulating NEP, and causing tau hyperphosphorylation [2], [3]. NEP is a synaptic enzyme which is found to play a major role in the clearance of Aβ from the brain [4]. The levels of NEP are declined with aging and hypoxic other diseases [8]. Patients suffering from cerebral ischemia and stroke in which hypoxic conditions occur are much more susceptible to AD [9]. Hypoxia inducible factor (HIF) is one of the early response molecules to hypoxic condition and HIF and its pathways participate in many pathological processes of diseases including AD [2], [10], and over 300 genes are regulated by HIF [11]. Several studies including ours have demonstrated that hypoxia increases the production of Aβ [2], [10], decreases the clearance of Aβ from brain [12] and increases tau phosphorylation [13]. Epigenetic changes play a key role in hypoxia-mediated gene expression change at transcriptional levels [14]. The methylation of CpG islands in the promoter regions of genes can result in the silenced expression [15]. Post-translational modification of histones by regulating cellular gene expression plays a critical role in sustained CpG island methylation [16]. Further, it has been reported that DNA methyltransferase inhibitor 5-Aza reduced the level of H3-K9 methylation in the promoter region of tumor suppressor gene independently of cytosine methylation [17], suggesting a novel function of 5-Aza in histone modification. It has also been demonstrated that post-translational modification of histones can control gene activity. The methylation and acetylation of lysine residues in histones by specific histone methyltrans-
ferases (HMTs) [17] and histone deacetylase (HDACs) [18] have been implicated in the alterations of chromatin structure and gene regulation. The methylation of K9 and demethylation of K4 in histone 3 has been associated with condensed chromatin and the silencing of genes [19], and the deacetylation of lysine in histone 3 has been linked to chromatin condensing and gene silencing [18].

In the present study, we have shown that hypoxia causes significant down-regulation of NEP expression, which can be prevented by methylation inhibitor 5-Aza, HDAC inhibitor VA, and siRNA-mediated knockdown of G9a or HDAC1. Our results suggest that chromatin remodeling of crucial AD-related genes by 5-Aza, VA and G9a or HDAC1 inhibitors could provide new therapeutic strategy for AD.

Results
Hypoxia inhibits the expression of NEP at the mRNA and protein levels

In order to detect whether hypoxia can affect the expression of NEP, NEP expression was detected by real-time PCR and Western blot after hypoxic treatment for 12 h, 24 h and 48 h in mouse primary cortical and hippocampal neurons and astrocytes. Our results showed that hypoxia significantly inhibited the expression of NEP both at the mRNA and protein levels (Figure 1A–C) in mouse primary cortical and hippocampal neurons after hypoxic treatment for 24 h and 48 h. But in astrocytes hypoxia did not affect the expression of NEP (Figure 1A–C).

The epigenetic regulators 5-Aza and VA were utilized to examine the epigenetic role in the down-regulation of NEP by hypoxia at the mRNA and protein levels. We found that 5-Aza and VA prevented the down-regulation of NEP via inhibiting cytosine methylation [20], diminishing H3-K9 methylation [17], augmenting H3 acetylation and H3-K4 methylation [21], while VA may prevent the down-regulation of NEP via augmenting H3 acetylation by inhibiting HDACs [22]. These results suggest that either histone/DNA methylation or histone deacetylation is involved in the down-regulation of NEP by hypoxia.

Histone methylation is involved in hypoxia-induced downregulation of NEP

Since H3K9me2 is known to cause gene silencing [17], we further determined the H3K9me2 status during hypoxia. We found that H3K9me2 levels were significantly increased in mouse primary cortical and hippocampal neurons after hypoxic treatment for 24 h and 48 h (Figure 2A, B). As H3-K4 trimethylation (H3K4me3) was reported to be involved in gene activation [17], we examined H3K4me3 levels in the mouse primary cortical and

![Figure 1](https://example.com/figure1.png)

**Figure 1. Hypoxia inhibits the expression of NEP at the protein and mRNA levels.** (A) NEP mRNA expression was determined by real-time PCR. Primary cortical and hippocampal neurons and astrocytes were incubated under the condition of normoxia or hypoxia for 12 h, 24 h, and 48 h. NEP mRNA transcript levels in normoxic control cells were normalized against GAPDH. (B, C) Primary cortical and hippocampal neurons and astrocytes were incubated under the condition of normoxia or hypoxia for 12 h, 24 h, and 48 h. The protein of β-actin was blotted as control. (D) Primary cortical and hippocampal neurons were incubated under the condition of normoxia or hypoxia for 24 h. Cells were treated with 5-Aza (100 mM) and VA (10 mM) before hypoxia. NEP mRNA transcript levels in normoxic control cells were normalized against GAPDH. (E, F) Primary cortical and hippocampal neurons were cultured for 24 h in the presence of S-Aza, VA or no drug. As control, the protein levels of β-actin were blotted with anti-β-actin antibody. Data are expressed as mean ± SD from four separate experiments. *P<0.05, **P<0.01 as compared with Sham; #P<0.05 as compared with H24h. O.D., optical density; Sham, normoxia; H, hypoxia; S-Aza, S-Aza-2-deox-ycyttri-dine; VA, sodium valproate; GAPDH, glyceraldehydes-3-phosphate dehydrogenase.

doi:10.1371/journal.pone.0019229.g001
Hypoxia Decreased the Expression of Neprilysin

Histone deacetylation is involved in hypoxia-induced down-regulation of NEP

Histone deacetylation is known to be involved in gene silencing [17] and HDAC1 is the most important histone deacetylase. Therefore we determined the H3-Ace and HDAC1 status in the primary cortical and hippocampal neurons under the hypoxic condition. We found that histone acetylation was significantly decreased while HDAC1 was significantly increased in the neuronal cultures after treatment for 24 h or 48 h of hypoxia (Figure 4A, B). H3-Ace and HDAC1 expressions were inversely correlated after 24 h or 48 h of hypoxia in the neuronal cultures (Figure 4A, B).

To verify whether histone acetylation under hypoxic condition can result in NEP down-regulation, we performed ChIP assay and q-PCR to determine the interaction of H3-Ace and NEP promoters. As shown in Figure 4C and D, hypoxia decreased the binding of H3-Ace to the NEP promoters. Compared to the input control, promoter H3-Ace was lower in the normoxia-treated cultures than in hypoxia-treated ones. These results indicate that hypoxia could induce histone deacetylation through NEP promoter regions, leading to down-regulation of NEP expression (Figure 4C, D).

It has been reported that HDAC1 can modulate histone deacetylation under hypoxic condition [25], [26]. Thus, we investigated whether HDAC1 contributes to in the histone deacetylation of NEP promoters in association with hypoxia-induced NEP down-regulation. We transfected mouse primary cortical and hippocampal neurons with a siRNA of HDAC1 to knockdown HDAC1 and a scrambled siRNA of HDAC1 as a control. As shown in Figure 5A–D, the treatment with HDAC1 siRNAs significantly attenuated the hypoxia-induced increase in the expression of HDAC1 by 62% and 41% in the primary cortical and hippocampal neurons, respectively. Further, the treatment with HDAC1 siRNAs significantly prevented the hypoxia-induced decrease in the expressions of H3-Ace and NEP by 29%–36% and 27%–31% in mouse primary cortical and hippocampal neurons, respectively (Figure 5A–D). Application of scrambled siRNA of HDAC1 seemed no interference with the expressions of HDAC1, H3-Ace and NEP (Figure 5A–D). In addition, we performed an immunocytochemistry study in the neuronal cultures, illustrating that HDAC1 siRNA prevented the hypoxia-induced H3-Ace down-regulation, which was correlated with the results from Western blot (Figure 5E). These findings suggest that hypoxia can suppress NEP expression through histone deacetylation by HDAC1.

Histone deacetylation is involved in hypoxia-induced down-regulation of NEP

DNA promoters methylation in hypoxia-induced down regulation of NEP

To determine whether hypoxia can regulate DNA methylation of NEP promoters, we performed methylation-specific PCR assay with the primers designed to amplify NEP promoter regions in the mouse primary cortical and hippocampal neurons. The results showed no obvious change in the levels of unmethylation-specific PCR and methylation-specific PCR under 48 h hypoxic condition as compared with normoxic treatment, suggesting that there was no evidence of hypoxia-induced methylation at CpG sites (Figure 6A). Next we detected the levels of DNMT1 and DNMT3a and found that both of them were significantly increased in the primary hippocampal neurons after hypoxic treatment for 24 h and 48 h, but were only significantly increased in the cortical neurons after hypoxic treatment for 48 h (Figure 6B, C). These results indicate that hypoxia induces significantly changes in DNMT1 and DNMT3a expressions, but the DNA methylation PCR data do not support that hypoxia affects the methylation of NEP promoters.

Discussion

Abnormal deposition of Aβ in brain is the most significant and important pathological hallmark of AD. Late-onset forms of AD might be primarily attributed to deficiency in the clearance of Aβ rather than its formation [1]. Aβ accumulation has been shown in part by the down regulation of several enzymes associated with degradation, including NEP. The NEP plays a major role in the clearance of Aβ from the brain [4], [27], [27], and over-expression of NEP is found to significantly reduce the Aβ burden in transgenic AD mice [28]. Increasing lines of evidence suggest that NEP levels in the brain declines with aging and chronic hypoxia, and the decreased NEP levels may lead to the reduction in Aβ clearance which may contribute the development and progression of AD [12], [29]. It is well documented that hypoxia is a risk factor for Aβ generation in vivo and in vitro through increasing Aβ generation by altering β-cleavage and γ-cleavage of APP and down-regulating NEP, and possible other pathways [2], [3]. Our results suggest that hypoxia affects the NEP expression both at mRNA and protein levels by regulating the histone methylation and histone deacetylation.
Figure 2. Hypoxia increases histone H3-K9me2 and G9a, but decreases H3K4me3.

(A, B) H3K9me2 and G9a of primary cortical and hippocampal neurons were detected by Western blot analysis at 24 h and 48 h after hypoxia. β-actin was used as control. (C, D) H3K4me3 was detected by Western blot analysis at 24 h and 48 h after hypoxia. Data are expressed as mean ± SD from four separate experiments. *P<0.05, **P<0.01 as compared with Sham; #P<0.05 as compared with H24 h. (E, F) ChIP and q-PCR analysis were performed with an anti-H3K9me2 antibody and primers amplifying the NEP promoter-1 and promoter-2 regions; the bands illustrate the levels of H3K9me2 in the NEP promoter-1 and promoter-2 regions. Ip represents amplification of total input DNA from whole neurons. H3K9 represents DNA bound to H3K9me2 in the sample. Results from four separate experiments are presented as the ratio of H3K9 to Ip. *P<0.05, **P<0.01 as compared with Sham; Sham, normoxia; H, hypoxia.

doi:10.1371/journal.pone.0019229.g002
It is increasingly acknowledged that epigenetic phenomena may be a crucial component in the development of complex brain disorders [30]. Indeed, it has been reported that epigenetic mechanisms play an important role in AD [31]. Furthermore, oxidative stress and hypoxia which are the common pathophysiologic contributors in AD [32] have been shown to modulate DNA methylation and histone methylation [33]. Analyses of DNA methylation and histone modulation in genes associated with AD from patients’ prefrontal cortex and lymphocytes have revealed abnormal profiles [33]. An age-specific epigenetic drift associated with unusual methylation patterns in late-onset forms of AD has been identified, supporting a potential epigenetic role in the development of AD [34]. Yet, increasing lines of evidence indicate that age and hypoxia may influence epigenetic drift in AD [35].

DNA methylation and demethylation is one of the mechanisms operating in the epigenetic regulation of gene expression. A few studies have shown that DNA methylation of the NEP promoters do not mediate its transcriptional repression in the neuronal lines [36] or in hepatobiliary cells in Alagille syndrome [37]. Meanwhile, hypoxic silencing of RUNX3 may not result from DNA promoter methylation [25]. The epigenetic regulator 5-Aza is known for its ability to inhibit cytosine methylation [20]. Some studies have also demonstrated that 5-
Aza is able to cause a regional remodeling of chromatin, by diminishing H3-K9 methylation and augmenting H3 acetylation and H3-K4 methylation, independently of its effects on DNA methylation or gene expression [17], [21]. It has also been reported that hypoxia can result in the down-regulation of MLH1 and RUNX3 by histone H3K9me2 through G9a [25], [26], [38] or through inhibiting histone demethylases JHDM2A or JMJD1A [39]. In our study, we found that hypoxia significantly increases the expressions of DNMT1 and DNMT3a, but does not affect the methylation of NEP promoters (Figure 6A). All the results indicate that 5-Aza may reverse hypoxia-induced down-regulation of NEP by diminishing H3-K9 methylation and augmenting H3 acetylation and H3-K4 methylation.

Post-translational modification of the N-terminal group of histone lysine residues by acetylation or deacetylation can regulate gene activity. HDACs especially HDAC1 play a critical role in sustained histone deacetylation in the gene promoter. Although much attention has focused on the potential function of HDACs in cancer research, recently there have been several studies showing their involvement in neurodegenerative diseases [22]. HDACs inhibitors can enhance the clearance of Aβ from brain [40] by inducing expression of plasmin [12], inhibit the Aβ production and neuritic plaque formation [41], and reverse the contextual memory deficits in a mouse model of AD [42]. In this study, we have demonstrated that hypoxia is able to reduce H3-Ace in the NEP promoters by enhancing HDAC1. However, the role of hypoxia in the neuropathology of AD is yet to be determined.

In summary, we have shown that hypoxia causes significant down-regulation of NEP expression by increasing H3K9me2, H3K1me3 and decreasing H3-Ace modulation, which can be prevented by the epigenetic regulators 5-Aza, HDACs inhibitor VA, siRNA-mediated knockdown of G9a or HDAC1. Chromatin remodeling of crucial AD related genes by 5-Aza, VA, and siRNA-mediated knockdown of HDAC1 or G9a can provide new therapeutic strategy for AD.

**Figure 4. Hypoxia decreases H3-Ace and increases HDAC1 expression.** (A, B) H3-Ace and HDAC1 of primary cortical and hippocampal neurons were detected at 24 h and 48 h by Western blot analysis. Exposure to hypoxia for 24 h and 48 h decreased H3-Ace, but increased the level of HDAC1. As control, α-tubulin was blotted. Data are expressed as mean ± SD from four separate experiments. *P<0.05, **P<0.01 as compared with Sham; #P<0.05, ##P<0.01 as compared with H24 h. (C, D) ChIP and q-PCR analysis were performed with an anti-H3-Ace antibody and primers amplifying the NEP promoter-1 and promoter-2 regions; the bands illustrate the levels of H3-Ace in the NEP promoter-1 and promoter-2 regions. Ip represents amplification of total input DNA from whole cell lysate. H3-Ace represents DNA bound to H3-Ace in the sample. Results from four separate experiments are presented as the ratio of H3-Ace to Ip. *P<0.05, **P<0.01 as compared with Sham; Sham, normoxia; H24 h, hypoxia 24 h. doi:10.1371/journal.pone.0019229.g004
Materials and Methods

Mouse primary cortical and hippocampal neuron and astrocyte cultures

Animal care and procedures were performed in accordance with the Laboratory Animal Care Guidelines approved by Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences. Permit numbers: SCXK (HU) 2007–0005; SYXK (HU) 2008–0049. This study was approved by Science and Technology Commission of Shanghai Municipality.

The C57 mouse primary cortical and hippocampal neurons and astrocytes were prepared according to previously described procedures. Briefly, primary cortical and hippocampal neurons and astrocytes were grown from dissociated cells derived from the cerebral cortex and hippocampus of 24 h old C57 mouse (Experimental Animal Center of Shanghai). After the cerebral cortex and hippocampus were removed and meninges and microvessels were cleaned, the cortex and hippocampus tissues were cut into 1–2 mm³ pieces and then digested with 0.05% trypsin-EDTA (Sigma, USA) and 0.01% DNase I (Sigma, USA) at 37°C for 15 min, then

Figure 5. Hypoxia decreases H3-Ace through HDAC1 accumulation. (A, B, C, D) Primary cortical and hippocampal neurons were transfected with HDAC1 siRNA, followed by hypoxic exposure for 24 h. HDAC1, H3-Ace and NEP protein levels were evaluated by Western blot. The HDAC1 siRNA decreased the expression of HDAC1, increased the expression of H3-Ace, and increased the expression of NEP. As control, the protein α-tubulin was blotted. Data are expressed as mean ± SD from four separate experiments. *P<0.05, **P<0.01 and ***P<0.001 as compared with Sham; #P<0.05, ##P<0.01 as compared with H24 h. (E) Immunocytochemical detection of H3-Ace of primary cortical neurons. (a) Sham. (b) Hypoxia. (c) Transfected with scrambled HDAC1 siRNA as control. (d) Transfected with HDAC1 siRNA. Neurons were stained with antibody against H3-Ace followed by a FITC-labeled secondary antibody. The HDAC1 siRNA prevented the hypoxia induced down-regulation of H3-Ace. Magnification: 400 ×. Scale bars, 20 μm. O.D., optical density; Sham, normoxia; H24 h, hypoxia 24 h; Sc-siRNA, scrambled siRNA of HDAC1; siRNA, siRNA of HDAC1.

doi:10.1371/journal.pone.0019229.g005
terminated with culture media. The culture medium consisted of Neurobasal™ medium (Gibco, USA), supplemented with 10% FCS (Gibco, USA), 2% (f/c) B-27 supplement (Gibco, USA), 5 mM (f/c) L-glutamine (Sigma, USA), and 10 mg/ml gentamycin (Sigma, USA). After mechanical dissociation, centrifugation, and resuspension, the cells were seeded in 6-well or 24-well tissue culture plates (Coning, USA) at a density of 1 \times 10^5/cm^2. After culture for 2 weeks, these preparations were referred to as "neuronal cultures" to contain over 90% neurons as illustrated by MAP2 immunostaining [43]. Cells were treated with 5-Aza (100 mM) and VA (10 mM) before hypoxia.

For preparation of astrocytes, B-27 wasn’t added to the medium. After culture for 2 weeks, the astrocytes in flasks (Coning, USA) were shaken at 190 rpm for 18 h at 37°C to remove microglia and oligodendrocytes. Next, the attached cells were digested with 0.25% trypsin-EDTA and transferred to 6-well plates at a density of 1.5 \times 10^5/cm^2. Using GFAP immunostaining we documented nearly 95% cells GFAP-positive astrocytes [44].

**Hypoxic stress**

To study the effect of hypoxia on expression and localization of proteins of interest, the C57 mouse primary cortical and hippocampal neurons and astrocytes were incubated in an O\textsubscript{2}/N\textsubscript{2}/CO\textsubscript{2} incubator MCO-M (Sanyo, Japan) for 12 h, 24 h or 48 h under 1% O\textsubscript{2} in accordance with previous reports [45]. The cells were collected 12 h, 24 h or 48 h later, washed twice with 10 ml phosphate buffered Saline (PBS, pH 7.2), scraped into 10 ml of PBS and pelleted at 3,000 g for 5 min. Pellets were resuspended in 6 x vol of 50 mM Tris-1% Triton X-100 (pH 7.4) buffer containing an EDTA free cocktail of protease inhibitors in the concentration suggested by the manufacturer and lysed for 30 min at 4°C. Cell lysates were centrifuged at 12000 g for

---

**Figure 6. Methylation of NEP promoter regions and DNMT levels.** (A) Methylation-specific PCR analysis of the NEP promoter-1 and promoter-2 regions were performed with genomic cDNA isolated as described in materials and methods. Methylation was detected by the presence of PCR product amplified by methylation-specific primers in the Meth lane; demethylation was detected using PCR products amplified with unmethylated-specific primers in the Ume lane. (B, C) DNMT1 and DNMT3a were detected at 24 h and 48 h by Western blot. As control, α-tubulin was blotted. Data are expressed as mean ± SD from four separate experiments. *P<0.05 as compared with Sham; #P<0.05 as compared with H24 h; Sham, normoxia; H48h, hypoxia 48 h; Ume, unmethylated; Meth, methylation.

doi:10.1371/journal.pone.0019229.g006
20 min and the supernatants were analyzed for protein concentration and used either for Western blotting.

Real-Time PCR Analysis

Total RNA from cultures was prepared using Trizol reagent (Invitrogen, USA) and digested with RNase-free DNase for 30 min to exclude genomic DNA contamination. For RT-PCR analysis, 2 mg of RNA was transcribed into cDNA with the Reverse Transcription System (Promega, USA) and oligo (dT) primers in a 20-μl volume. The abundance of transcripts in cDNA samples was measured by RT-PCR with primer as follows: NEP forward, 5'-ATCCACAGATTGTGTTAAGGA-3', reverse, 5'-GCCAGGGACTAAA-3'; GAPDH forward, 5'-CCATGTTTGATGGGTGGAACCA-3', reverse, 5'-ACCACTG GATGCCAGGGATGATGTTC-3' (Sangon Biotech, China). Real-time PCR was performed by Chromo 4 Sequence Detection System (Bio-Rad, USA) utilizing a SYBR Green PCR premix reagent.

Methylation-specific PCR and unmethylation-specific PCR

Genomic DNA was extracted by a standard proteinase K digestion and phenol-chloroform procedure. Genomic DNA was modified by EZ DNA Methylation Direct™ Kit (Zymo Research, USA) according to the manufacturer’s protocol. After modification, PCR amplifications were performed with 40 cycles at 95°C for 30 s, 57–62°C for 30 s and 72°C for 30 s in a Peltier Thermal Cycler (Bio-Rad, USA). The primer sequences for the unmethylated products were promoter-1: forward, 5'-TTCCCTGAAGTGAGGGGTG-3', reverse, 5'-CCTCCTGCTCTGTTTCTT-3' (177 bp); promoter-2: forward, 5'-AGATGGTGCAAGTGCGGAGA-3', reverse, 5'-CGCACCCACAGAGACTCAC-3' (150 bp); The primer sequences for the methylated products were MS-promoter-1: forward, 5'-GAAC TCGCAAGACGAAGAAC-3', reverse, 5'-ATTATGGGAATTTGGTTTCGC-3' (183 bp); MSpromoter-2: forward, 5'-TCTCTGGTCTGTTGTTGTGTT-3', reverse, 5'-TCCCAGAACAATACACACACAA-3' (165 bp).

Transient transfection and siRNA silencing

One double-stranded siRNAs designed to target G9a and HDAC1, and a scrambled siRNA were synthesized as control (Gene Pharma Co., Ltd, China). Transfection with Lipofectamine 2000 (Invitrogen, USA) was performed according to the manufacturer’s protocol. Mouse primary cortical and hippocampal neurons were transfected with 100 nM duplexes targeted to G9a and HDAC1, and a scrambled siRNA were treated as control before hypoxia. G9a and HDAC1 protein expression were evaluated by Western blot after 24 h post-transfection. siRNA for G9a were designed to target 5'-AAGCTCTAACCTGACACACTAAA-3' and 5'-CACCATGAACATGATCGCCA-3', and siRNAs for HDAC1 were designed to target 5'-CACC GGGAGGAAGTCTGTTA-3' and 5'-GAGGAGGAGAGAACAGAAC-3' [25].

Statistical analysis

Significant differences between experimental groups were determined using one-way analysis of variance (ANOVA) with Sigma Stat. P value of less than 0.05 was considered to have significant difference. The quantitative data were obtained from 4 to 5 independent assays with duplication in each assay.

Acknowledgments

The authors acknowledge the joint participation by Diana Helis Henry Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine and this program. The authors would like to thank Prof. Degui Chen (The Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences), H3-Kme2 antibodies and H3-Kme3 antibodies.

Author Contributions

Conceived and designed the experiments: ZW WL. Performed the experiments: ZW DY XZ TL JL YT. Analyzed the data: ZW DY TL JL YT. Contributed reagents/materials/analysis tools: ZW XZ WL. Wrote the paper: ZW DY WL. Obtained permission for use of the C57 mouse primary cortical and hippocampal neurons and astrocytes: ZW DY XZ.
References

1. Hama E, Saido TC (2005) Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 65: 491–500.

2. Li L, Zhang X, Yang D, Luo G, Chen S, et al. (2009) Hypoxia increases Abeta generation by altering beta- and gamma-actin cleavage of APP. Neurobiol Aging 30: 1091–1098.

3. Zhang X, Le W (2010) Pathological role of hypoxia in Alzheimer’s disease. Exp Neurol 223: 299–303.

4. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, et al. (2004) Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci 22: 3–11.

5. Carlson JA, Turner AJ (2002) Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 81: 1–8.

6. Fisk L, Nalivaeva NN, Boyle JP, Peers CS, Turner AJ (2007) Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurons and astrocytes. Neurochem Res 32: 1741–1748.

7. Minaee JS, Wu X, Monod Z, Chalmers K, Wilcock G, Loeve S, et al. (2006) Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65: 1012–1021.

8. Honig LS, Kukull W, Mayeux R (2005) Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology 64: 494–500.

9. Schneider JA, Wilson RS, Cochran EJ, Bienias JL, Arnold SE, et al. (2003) Relation of cerebral infarcts to dementia and cognitive function in older persons. Neurology 60: 1082–1086.

10. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, et al. (2007) Hypoxia-inducible factor alpaha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid gene expression. J Biol Chem 282: 10873–10880.

11. Anderson CJ, Hoare SF, Ashcroft M, Billalain AE, Keith WN (2006) Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25: 61–69.

12. Nalivaeva NN, Fisk LR, Belayev ND, Turner AJ (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Courier Alzheimer Res 3: 212–224.

13. Platter F, Anglo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281: 25457–25465.

14. Young JA, Sonman NS, Verdine GL, Bestor TH (1997) DNA (cytosine-5)-methyltransferases in mouse cells and tissues. Studies with a mechanism-based probe. J Biol Chem 270: 385–395.

15. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247–257.

16. Carson JA, Turner AJ (2002) Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 81: 1–8.

17. Takebayashi S, Nakao M, Fujita N, Sado T, Tamaka M, et al. (2001) 5-Aza-2’-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochem Biophys Res Commun 288: 921–926.

18. Ishimaru F, Shipp MA (1995) Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood 85: 3199–3207.

19. Li C, Boone RM, Hersh LB (1995) Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs. J Biol Chem 270: 5723–5728.

20. Lee SH, Kim J, Kim WH, Lee YM (2009) Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 28: 184–194.

21. Chen H, Yan Y, Davidson TL, Shankai Y, Costa M (2006) Hypoxia stress induces dimethylated histone H3 lysine 9 through histone methyletransferase G9a in mammalian cells. Cancer Res 66: 9009–9016.

22. Manyam S, Hughechi M, Takaki Y, Manuba T, Tani J, et al. (2005) Cerebrosplinal fluid neprilysin is reduced in prodromal Alzheimer’s disease. Ann Neurol 57: 832–842.

23. Marr KA, Rockenstein E, Mokhirjev A, Kindy MS, Hersh LB, et al. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23: 1992–1996.

24. Hersh LB, Rodgers DW (2008) Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 5: 225–231.

25. Abolmaaleky HM, Cheng KH, Farouze SW, Wilcox M, Glant SJ, et al. (2006) Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15: 3132–3143.

26. Scarpas S, Puso A, D’Anselmi F, Cavallaro RA (2003) Presenilin 1 gene silencing by S-deoxyadenosinohemine: a treatment for Alzheimer disease? FEBS Lett 541: 145–148.

27. Fowler BA, Whistler MH, Lipsky M, Wang G, Chen XQ (2004) Oxidative stress induced by lead, cadmium and arsenic mixtures: 30-day, 90-day, and 180-day drinking water studies in rats: an overview. Biomets 17: 567–568.

28. Campos AC, Molognoni A, Melo FH, Galldeiri LC, Carneiro CR, et al. (2007) Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 9: 1111–1121.

29. Wang SC, Oelze B, Schumacher A (2008) Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One 3: e2698.

30. Cacabelos R (2008) Pharmacogenomics in Alzheimer’s disease. Methods Mol Biol 446: 213–357.

31. Belayev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 10: 94–100.

32. Byrne JA, Meara NJ, Rayner AG, Thompson RJ, Kinsley AS (2007) Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome. Lab Invest 87: 1138–1148.

33. Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, et al. (2009) The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun 378: 57–61.

34. Chen H, Kuzu T, Zhang R, Costa M (2010) Hypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells. Carcinogenesis 31: 2136–2144.

35. Jacobsen JS, Comery TA, Martone RL, Ekelohal H, Cranfill DL, et al. (2008) Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 105: 8734–8739.

36. Kangore M, Miller KA, Fass DM, Hemmig KM, Haggarty SJ, et al. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropharmacology 55: 670–680.

37. Qin H, He G, Lewis MB, Forte DA, Debnath D, et al. (2008) Valproic acid induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 68: 6456–6461.

38. Nak Y, Gao HH, Johnson CA, Laherty CD, Turner BM, et al. (1998) Neuronal and astrocytic expression of a histone deacetylase complex. Nature 393: 386–389.

39. Fahmier JA, Eguchi S, Herman JG, Baylin SB (2002) Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62: 7213–7218.

40. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, et al. (1999) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95: 5246–5250.

41. Takebayashi S, Nakao M, Fujita N, Sado T, Tamaka M, et al. (2001) 5-Aza-2’-deoxycytidine induces histone hyperacylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochem Biophys Res Commun 288: 921–926.

42. Morsen BC, Madsen H, D’Mello SR (2007) Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64: 2250–2260.